Cargando…

Multiplatform profiling of pancreatic neuroendocrine tumors: Correlative analyses of clinicopathologic factors and identification of co-occurring pathogenic alterations

BACKGROUND: Multi-omic profiling of pancreatic neuroendocrine tumors (PanNETs) was performed to correlate genomic, proteomic, and molecular pathway alterations with clinicopathologic factors and identify novel co-occurring pathogenic alterations of potential clinical relevance to PanNET management....

Descripción completa

Detalles Bibliográficos
Autores principales: Gong, Jun, Blais, Edik M., Bender, Joseph R., Guan, Michelle, Placencio-Hickok, Veronica, Petricoin, Emanuel F., Pishvaian, Michael J., Gregory, Gary, Tuli, Richard, Hendifar, Andrew E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6817448/
https://www.ncbi.nlm.nih.gov/pubmed/31692857
http://dx.doi.org/10.18632/oncotarget.27265
_version_ 1783463422920228864
author Gong, Jun
Blais, Edik M.
Bender, Joseph R.
Guan, Michelle
Placencio-Hickok, Veronica
Petricoin, Emanuel F.
Pishvaian, Michael J.
Gregory, Gary
Tuli, Richard
Hendifar, Andrew E.
author_facet Gong, Jun
Blais, Edik M.
Bender, Joseph R.
Guan, Michelle
Placencio-Hickok, Veronica
Petricoin, Emanuel F.
Pishvaian, Michael J.
Gregory, Gary
Tuli, Richard
Hendifar, Andrew E.
author_sort Gong, Jun
collection PubMed
description BACKGROUND: Multi-omic profiling of pancreatic neuroendocrine tumors (PanNETs) was performed to correlate genomic, proteomic, and molecular pathway alterations with clinicopathologic factors and identify novel co-occurring pathogenic alterations of potential clinical relevance to PanNET management. METHODS: PanNETs referred to Perthera, Inc. having undergone molecular profiling for precision matched therapeutic purposes were screened. Correlative analyses were performed using Fisher’s exact test across individual pathogenic alterations or altered molecular pathways and clinicopathologic variables. Associations were visualized by hierarchical clustering. Prognostic associations with overall survival (OS) were identified using Cox regression for pathogenic alterations and pathway-level alterations. Hazard ratios (HR) and odds ratios (OR) were reported with 95% confidence intervals (CI). RESULTS: From 12/2014–1/2019, 46 patients with predominantly locally advanced and metastatic PanNETs were included. MEN1 alterations by next-generation sequencing (NGS) were less associated with having high-grade PanNETs and metastatic disease at diagnosis (p ≤ 0.05). Genomic alterations associated with increased replicative stress (primarily driven by RB1 and TP53) correlated with higher grade (OR 6.87 [95% CI: 1.57-35.18], p = 0.0043) and worse OS (HR 13.62 [95% CI: 1.51-122.5], p = 0.0198). Other significant associations included: ERCC1 protein expression with DAXX or MEN1 alterations (NGS), PTEN (NGS) with ARID1A or TP53 alterations (NGS), and history of diabetes coincided with cell cycle pathway alterations but was mutually exclusive with replicative stress pathway alterations. CONCLUSIONS: We identified several molecular signatures of potential clinical significance for therapeutic targeting and prognostication in PanNETs warranting prospective validation. Our findings are hypothesis generating and can inform larger molecular profiling efforts in PanNETs.
format Online
Article
Text
id pubmed-6817448
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-68174482019-11-05 Multiplatform profiling of pancreatic neuroendocrine tumors: Correlative analyses of clinicopathologic factors and identification of co-occurring pathogenic alterations Gong, Jun Blais, Edik M. Bender, Joseph R. Guan, Michelle Placencio-Hickok, Veronica Petricoin, Emanuel F. Pishvaian, Michael J. Gregory, Gary Tuli, Richard Hendifar, Andrew E. Oncotarget Research Paper BACKGROUND: Multi-omic profiling of pancreatic neuroendocrine tumors (PanNETs) was performed to correlate genomic, proteomic, and molecular pathway alterations with clinicopathologic factors and identify novel co-occurring pathogenic alterations of potential clinical relevance to PanNET management. METHODS: PanNETs referred to Perthera, Inc. having undergone molecular profiling for precision matched therapeutic purposes were screened. Correlative analyses were performed using Fisher’s exact test across individual pathogenic alterations or altered molecular pathways and clinicopathologic variables. Associations were visualized by hierarchical clustering. Prognostic associations with overall survival (OS) were identified using Cox regression for pathogenic alterations and pathway-level alterations. Hazard ratios (HR) and odds ratios (OR) were reported with 95% confidence intervals (CI). RESULTS: From 12/2014–1/2019, 46 patients with predominantly locally advanced and metastatic PanNETs were included. MEN1 alterations by next-generation sequencing (NGS) were less associated with having high-grade PanNETs and metastatic disease at diagnosis (p ≤ 0.05). Genomic alterations associated with increased replicative stress (primarily driven by RB1 and TP53) correlated with higher grade (OR 6.87 [95% CI: 1.57-35.18], p = 0.0043) and worse OS (HR 13.62 [95% CI: 1.51-122.5], p = 0.0198). Other significant associations included: ERCC1 protein expression with DAXX or MEN1 alterations (NGS), PTEN (NGS) with ARID1A or TP53 alterations (NGS), and history of diabetes coincided with cell cycle pathway alterations but was mutually exclusive with replicative stress pathway alterations. CONCLUSIONS: We identified several molecular signatures of potential clinical significance for therapeutic targeting and prognostication in PanNETs warranting prospective validation. Our findings are hypothesis generating and can inform larger molecular profiling efforts in PanNETs. Impact Journals LLC 2019-10-22 /pmc/articles/PMC6817448/ /pubmed/31692857 http://dx.doi.org/10.18632/oncotarget.27265 Text en http://creativecommons.org/licenses/by/3.0/ Copyright: Gong et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Paper
Gong, Jun
Blais, Edik M.
Bender, Joseph R.
Guan, Michelle
Placencio-Hickok, Veronica
Petricoin, Emanuel F.
Pishvaian, Michael J.
Gregory, Gary
Tuli, Richard
Hendifar, Andrew E.
Multiplatform profiling of pancreatic neuroendocrine tumors: Correlative analyses of clinicopathologic factors and identification of co-occurring pathogenic alterations
title Multiplatform profiling of pancreatic neuroendocrine tumors: Correlative analyses of clinicopathologic factors and identification of co-occurring pathogenic alterations
title_full Multiplatform profiling of pancreatic neuroendocrine tumors: Correlative analyses of clinicopathologic factors and identification of co-occurring pathogenic alterations
title_fullStr Multiplatform profiling of pancreatic neuroendocrine tumors: Correlative analyses of clinicopathologic factors and identification of co-occurring pathogenic alterations
title_full_unstemmed Multiplatform profiling of pancreatic neuroendocrine tumors: Correlative analyses of clinicopathologic factors and identification of co-occurring pathogenic alterations
title_short Multiplatform profiling of pancreatic neuroendocrine tumors: Correlative analyses of clinicopathologic factors and identification of co-occurring pathogenic alterations
title_sort multiplatform profiling of pancreatic neuroendocrine tumors: correlative analyses of clinicopathologic factors and identification of co-occurring pathogenic alterations
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6817448/
https://www.ncbi.nlm.nih.gov/pubmed/31692857
http://dx.doi.org/10.18632/oncotarget.27265
work_keys_str_mv AT gongjun multiplatformprofilingofpancreaticneuroendocrinetumorscorrelativeanalysesofclinicopathologicfactorsandidentificationofcooccurringpathogenicalterations
AT blaisedikm multiplatformprofilingofpancreaticneuroendocrinetumorscorrelativeanalysesofclinicopathologicfactorsandidentificationofcooccurringpathogenicalterations
AT benderjosephr multiplatformprofilingofpancreaticneuroendocrinetumorscorrelativeanalysesofclinicopathologicfactorsandidentificationofcooccurringpathogenicalterations
AT guanmichelle multiplatformprofilingofpancreaticneuroendocrinetumorscorrelativeanalysesofclinicopathologicfactorsandidentificationofcooccurringpathogenicalterations
AT placenciohickokveronica multiplatformprofilingofpancreaticneuroendocrinetumorscorrelativeanalysesofclinicopathologicfactorsandidentificationofcooccurringpathogenicalterations
AT petricoinemanuelf multiplatformprofilingofpancreaticneuroendocrinetumorscorrelativeanalysesofclinicopathologicfactorsandidentificationofcooccurringpathogenicalterations
AT pishvaianmichaelj multiplatformprofilingofpancreaticneuroendocrinetumorscorrelativeanalysesofclinicopathologicfactorsandidentificationofcooccurringpathogenicalterations
AT gregorygary multiplatformprofilingofpancreaticneuroendocrinetumorscorrelativeanalysesofclinicopathologicfactorsandidentificationofcooccurringpathogenicalterations
AT tulirichard multiplatformprofilingofpancreaticneuroendocrinetumorscorrelativeanalysesofclinicopathologicfactorsandidentificationofcooccurringpathogenicalterations
AT hendifarandrewe multiplatformprofilingofpancreaticneuroendocrinetumorscorrelativeanalysesofclinicopathologicfactorsandidentificationofcooccurringpathogenicalterations